Clinical efficacy and safety of Kangbusipu combined with leazu monoclonal antibody in the treatment of diabetic macular degeneration
10.3969/j.issn.1005-1678.2017.04.130
- VernacularTitle:康柏西普联合雷珠单抗治疗糖尿病性黄斑病变患者的临床疗效及安全性
- Author:
Jing YANG
;
Xi CHEN
- Keywords:
diabetic macular degeneration;
conbercept;
lucentis;
clinical efficacy;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(4):394-396
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of conbercept and lucentis in the treatment of age-related macular degeneration.Methods A total of 66 patients with age-related macular degeneration from our hospital were chosen,the patients or family members signed an agreement,were randomly divided into experiment group and control group with 33 cases in each group.Patients in the control group were treated by lucentis injection therapy; patients in the experiment group were treated by conbercept injection,determined serological indexes and ophthalmic indexes before and after treatment,and the clinical efficacy wascompared,the patients were followed up,the adverse reactions were recorded.Results After treatment,the vision restoration effective rate of the control group 48％was lower than the experiment group 80％,with statistical significance(P<0.05); the adverse reactions rate of the experiment group(20％)compared with the control group(16％),was no difference.Conclusion Conbercept injection in the treatment of age-related macular degeneration can decrease peripheral blood VEGF and CRP contents,reduce the CMT and CNV levels,reduce intraocular pressure,improve vision.
